Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O00744

UPID:
WN10B_HUMAN

ALTERNATIVE NAMES:
Protein Wnt-12

ALTERNATIVE UPACC:
O00744; B2R7A5; O00747; Q4VAJ4; Q4VAJ5; Q8WZ97

BACKGROUND:
The Protein Wnt-10b, alternatively named Protein Wnt-12, activates the Wnt signaling cascade, specifically the canonical Wnt/beta-catenin pathway. This activation triggers beta-catenin/LEF/TCF-mediated transcriptional programs, influencing stemness, pluripotency, and cell fate decisions. Its roles are critical in the immune system, mammary gland, adipose tissue, bone, and skin.

THERAPEUTIC SIGNIFICANCE:
Given Protein Wnt-10b's critical role in diseases like Split-hand/foot malformation 6 and selective Tooth agenesis 8, it represents a promising target for drug discovery. Understanding the role of Protein Wnt-10b could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.